Sarcomas are a heterogeneous group of malignant neoplasms of mesenchymal origin. Soft tissue sarcoma (STS) are tumors arising from mesenchymal cells that harbor de-regulation of pathways and chromosomal aberrations governing the morphogenesis of tissue. STS accounts for ~7% of cancers in children and 1% of cancers in adults. About half of the children that have soft tissue sarcoma are with rhabdomyosarcoma (RMS), which is a high-grade, aggressive and highly malignant form of cancer that develops from skeletal (striated) muscle cells and failed to fully differentiate.

Two major molecular and histopathological subtypes of RMS, "alveolar" RMS (ARMS) and "embryonic" RMS (ERMS), which are driven by fundamentally different mechanisms. We utilized multi-omics technology to unleash differences between both subtypes. Our findings revealed initially a substantial metabolic and proteomics differences that enables a quick and rapid identification of RM subtypes. The study provides a platform for better predicting the biomarkers of different RMS subgroups based on their omics profiles.